Goldman Sachs Group Inc. Has $3.07 Million Position in ClearPoint Neuro, Inc. $CLPT

Key Points

• Goldman Sachs Group Inc. increased its stake in ClearPoint Neuro by 98.3% in Q1, owning approximately 257,871 shares worth $3.07 million.
• ClearPoint Neuro's stock has seen a decline of 1.3% recently, with a current price of $11.20, while it holds a market cap of $318.42 million and a negative PE ratio of -13.83.
• Analysts currently rate ClearPoint Neuro with a consensus "Buy" and a target price of $19.67, reflecting a potential upside from its recent trading price.

Goldman Sachs Group Inc. increased its holdings in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) by 98.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 257,871 shares of the company's stock after acquiring an additional 127,823 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.92% of ClearPoint Neuro worth $3,066,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Millennium Management LLC raised its stake in ClearPoint Neuro by 156.3% during the first quarter. Millennium Management LLC now owns 741,193 shares of the company's stock worth $8,813,000 after acquiring an additional 452,043 shares during the period. Lane Generational LLC raised its stake in ClearPoint Neuro by 53.5% during the first quarter. Lane Generational LLC now owns 242,045 shares of the company's stock worth $2,878,000 after acquiring an additional 84,350 shares during the period. Conway Capital Management Inc. raised its stake in ClearPoint Neuro by 31.1% during the first quarter. Conway Capital Management Inc. now owns 211,325 shares of the company's stock worth $2,513,000 after acquiring an additional 50,100 shares during the period. Parsons Capital Management Inc. RI raised its stake in ClearPoint Neuro by 0.7% during the first quarter. Parsons Capital Management Inc. RI now owns 142,536 shares of the company's stock worth $1,695,000 after acquiring an additional 963 shares during the period. Finally, Trexquant Investment LP raised its stake in ClearPoint Neuro by 8.0% during the first quarter. Trexquant Investment LP now owns 84,653 shares of the company's stock worth $1,007,000 after acquiring an additional 6,291 shares during the period. Institutional investors and hedge funds own 30.08% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Wall Street Zen raised ClearPoint Neuro from a "sell" rating to a "hold" rating in a report on Saturday, September 13th. Stifel Nicolaus increased their price objective on ClearPoint Neuro from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $19.67.

ClearPoint Neuro Trading Up 2.6%

ClearPoint Neuro stock traded up $0.31 during midday trading on Tuesday, reaching $12.34. The stock had a trading volume of 73,150 shares, compared to its average volume of 313,403. The firm's fifty day simple moving average is $10.86 and its two-hundred day simple moving average is $11.92. ClearPoint Neuro, Inc. has a twelve month low of $9.76 and a twelve month high of $19.22. The company has a debt-to-equity ratio of 1.46, a current ratio of 7.30 and a quick ratio of 6.45. The firm has a market cap of $350.83 million, a price-to-earnings ratio of -15.24 and a beta of 0.89.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). ClearPoint Neuro had a negative return on equity of 94.44% and a negative net margin of 66.15%.The firm had revenue of $9.22 million during the quarter, compared to analyst estimates of $9.20 million. ClearPoint Neuro has set its FY 2025 guidance at EPS. Equities analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 EPS for the current fiscal year.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.